Serum Prostatic Specific Antigen Changes After Bipolar and Monopolar TURP
1 other identifier
interventional
2
0 countries
N/A
Brief Summary
To use PSA levels after bipolar and monopolar transurethral resection of the benign prostatic hyperplasia as an indicator of the quality of resection .
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Oct 2022
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 5, 2022
CompletedFirst Posted
Study publicly available on registry
September 8, 2022
CompletedStudy Start
First participant enrolled
October 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2023
CompletedSeptember 8, 2022
September 1, 2022
1 year
September 5, 2022
September 7, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
serum PSA changes after bipolar and monopolar transurethral resection of the benign prostatic hyperplasia
To use PSA levels changes after both techniques (bipolar and monopolar transurethral resection of the benign prostatic hyperplasia)as an indicator of the quality of resection
within one month after intervention
Secondary Outcomes (1)
International Prostate Symptom Score
within one month after intervention
Study Arms (2)
Bipolar TURP
ACTIVE COMPARATORPatients thats will undergo bipolar TURP
Monopolar TURP
ACTIVE COMPARATORPatients thats will undergo monopolar TURP
Interventions
Bipolar and monopolar transurethral resection of the benign prostatic hyperplasia
Eligibility Criteria
You may qualify if:
- Patients agreeing to participate, clinically fit, age from 50 to 80 years with LUTS related to benign prostate enlargement with no neurological disorder
You may not qualify if:
- Prostate cancer
- Previous urethral or prostate surgery
- Neurogenic bladder
- Urethral stricture
- Patient unfit for surgery
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (2)
Geavlete B, Georgescu D, Multescu R, Stanescu F, Jecu M, Geavlete P. Bipolar plasma vaporization vs monopolar and bipolar TURP-A prospective, randomized, long-term comparison. Urology. 2011 Oct;78(4):930-5. doi: 10.1016/j.urology.2011.03.072. Epub 2011 Jul 29.
PMID: 21802121RESULTPahwa M, Pahwa M, Pahwa AR, Girotra M, Chawla A, Sharma A. Changes in S-PSA after transurethral resection of prostate and its correlation to postoperative outcome. Int Urol Nephrol. 2013 Aug;45(4):943-9. doi: 10.1007/s11255-013-0474-3. Epub 2013 May 24.
PMID: 23703547RESULT
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Mohamed A Elgamal, professor
Assiut University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
September 5, 2022
First Posted
September 8, 2022
Study Start
October 1, 2022
Primary Completion
October 1, 2023
Study Completion
November 1, 2023
Last Updated
September 8, 2022
Record last verified: 2022-09